Bionomics to Present at the 2024 CNS Summit

Rhea-AI Summary

Bionomics (BNOX), a clinical-stage biotech company focused on developing first-in-class allosteric ion channel modulators for CNS disorders, has announced its participation in the 15th CNS Summit. The event will take place from November 10-13, 2024, at the Encore Boston Hotel in Boston, MA.

Dr. Spyros Papapetropoulos, President and CEO, will deliver a company presentation during the Neuroscience Spotlight session on Tuesday, November 12 at 1:00 p.m. ET in the Picasso ballroom. The presentation will subsequently be available on Bionomics' website under the Events page in the Investors Center section.

ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be participating and presenting at the 15^th CNS Summit being held November 10-13, 2024 at the Encore Boston Hotel in Boston, MA.

Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will deliver a company presentation during the Neuroscience Spotlight session taking place on Tuesday, November 12 at 1:00 p.m. ET in the Picasso ballroom.

Following the event, the presentation will be posted to Bionomics’ website under the “Events” page of the Investors Center section.

FOR FURTHER INFORMATION PLEASE CONTACT:

General Rajeev Chandra Company Secretary CoSec@bionomics.com.au	Investor Relations Kevin Gardner kgardner@lifesciadvisors.com	Investor Relations Chris Calabrese ccalabrese@lifesciadvisors.com

About Bionomics Limited
Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other CNS conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. www.bionomics.com.au

Forward-Looking Statements
Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the closing of each tranche of the Company’s private placement financing, the achievement of certain milestones for the various tranches, the timely funding to the Company by each investor in the private placement, the timing, size and expectation of the closing of the private placement; and expectations regarding market conditions, the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom; and the Company’s expectation that its current cash, cash equivalents, and marketable securities will fund our operations into the third quarter of 2025. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including, but not limited to, the Company’s Annual Report on Form 20-F filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Bionomics’ filings with the SEC, copies of which are available from the SEC’s website (www.sec.gov) and on Bionomics’ website (www.bionomics.com.au) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Bionomics expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

FAQ

When is Bionomics (BNOX) presenting at the 2024 CNS Summit?

Bionomics (BNOX) will present during the Neuroscience Spotlight session on Tuesday, November 12, 2024, at 1:00 p.m. ET in the Picasso ballroom.

Where will the 2024 CNS Summit featuring Bionomics (BNOX) be held?

The 15th CNS Summit will be held at the Encore Boston Hotel in Boston, MA, from November 10-13, 2024.

What type of treatments is Bionomics (BNOX) developing?

Bionomics is developing novel, first-in-class, allosteric ion channel modulators to treat patients with serious central nervous system (CNS) disorders with high unmet medical need.

Will Bionomics (BNOX) make their CNS Summit presentation available online?

Yes, following the event, the presentation will be posted to Bionomics' website under the 'Events' page of the Investors Center section.